Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial

Scott Klarenbach, Marcello Tonelli, Robert Pauly, Michael Walsh, Bruce Culleton, Helen So, Brenda Hemmelgarn, Braden Manns, Scott Klarenbach, Marcello Tonelli, Robert Pauly, Michael Walsh, Bruce Culleton, Helen So, Brenda Hemmelgarn, Braden Manns

Abstract

Provider and patient enthusiasm for frequent home nocturnal hemodialysis (FHNHD) has been renewed; however, the cost-effectiveness of this technique is unknown. We performed a cost-utility analysis of FHNHD compared with conventional hemodialysis (CvHD; 4 hours three times per week) from a health payer perspective over a lifetime horizon using patient information from the Alberta NHD randomized controlled trial. Costs, including training costs, were obtained using microcosting and administrative data (CAN$2012). We determined the incremental cost per quality-adjusted life year (QALY) gained. Robustness was assessed using scenario, sensitivity, and probabilistic sensitivity analyses. Compared with CvHD (61% in-center, 14% satellite, and 25% home dialysis), FHNHD led to incremental cost savings (-$6700) and an additional 0.38 QALYs. In sensitivity analyses, when the annual probability of technique failure with FHNHD increased from 7.6% (reference case) to ≥19%, FHNHD became unattractive (>$75,000/QALY). The cost/QALY gained became $13,000 if average training time for FHNHD increased from 3.7 to 6 weeks. In scenarios with alternate comparator modalities, FHNHD remained dominant compared with in-center CvHD; cost/QALYs gained were $18,500, $198,000, and $423,000 compared with satellite CvHD, home CvHD, and peritoneal dialysis, respectively. In summary, FHNHD is attractive compared with in-center CvHD in this cohort. However, the attractiveness of FHNHD varies by technique failure rate, training time, and dialysis modalities from which patients are drawn, and these variables should be considered when establishing FHNHD programs.

Figures

Figure 1.
Figure 1.
Diagram of model comparing CvHD with FHNHD. Patients on CvHD either continue CvHD or commence training for FHNHD. Patients may stay in a health state (circle) or transition to other health states (arrows) as defined by transition probabilities. Tx, transplant.

References

    1. Canadian Institute for Health Information : Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, Ottawa, ON, Canada, Canadian Institute for Health Information, 2011
    1. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, Manns BJ: Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: A randomized controlled trial. JAMA 298: 1291–1299, 2007
    1. Walsh M, Culleton B, Tonelli M, Manns B: A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 67: 1500–1508, 2005
    1. Manns BJ, Walsh MW, Culleton BF, Hemmelgarn B, Tonelli M, Schorr M, Klarenbach S: Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis. Kidney Int 75: 542–549, 2009
    1. Rocco MV, Lockridge RS, Jr., Beck GJ, Eggers PW, Gassman JJ, Greene T, Larive B, Chan CT, Chertow GM, Copland M, Hoy CD, Lindsay RM, Levin NW, Ornt DB, Pierratos A, Pipkin MF, Rajagopalan S, Stokes JB, Unruh ML, Star RA, Kliger AS, Kliger A, Eggers P, Briggs J, Hostetter T, Narva A, Star R, Augustine B, Mohr P, Beck G, Fu Z, Gassman J, Greene T, Daugirdas J, Hunsicker L, Larive B, Li M, Mackrell J, Wiggins K, Sherer S, Weiss B, Rajagopalan S, Sanz J, Dellagrottaglie S, Kariisa M, Tran T, West J, Unruh M, Keene R, Schlarb J, Chan C, McGrath-Chong M, Frome R, Higgins H, Ke S, Mandaci O, Owens C, Snell C, Eknoyan G, Appel L, Cheung A, Derse A, Kramer C, Geller N, Grimm R, Henderson L, Prichard S, Roecker E, Rocco M, Miller B, Riley J, Schuessler R, Lockridge R, Pipkin M, Peterson C, Hoy C, Fensterer A, Steigerwald D, Stokes J, Somers D, Hilkin A, Lilli K, Wallace W, Franzwa B, Waterman E, Chan C, McGrath-Chong M, Copland M, Levin A, Sioson L, Cabezon E, Kwan S, Roger D, Lindsay R, Suri R, Champagne J, Bullas R, Garg A, Mazzorato A, Spanner E, Rocco M, Burkart J, Moossavi S, Mauck V, Kaufman T, Pierratos A, Chan W, Regozo K, Kwok S, Frequent Hemodialysis Network (FHN) Trial Group : The effects of frequent nocturnal home hemodialysis: The Frequent Hemodialysis Network Nocturnal Trial. Kidney Int 80: 1080–1091, 2011
    1. Komenda P, Levin A, Manns B: The economics of home nocturnal hemodialysis: How should we cost the benefits? Clin Nephrol 68: 151–158, 2007
    1. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA: The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int 64: 1004–1011, 2003
    1. McFarlane PA, Pierratos A, Redelmeier DA: Cost savings of home nocturnal versus conventional in-center hemodialysis. Kidney Int 62: 2216–2222, 2002
    1. Kroeker A, Clark WF, Heidenheim AP, Kuenzig L, Leitch R, Meyette M, Muirhead N, Ryan H, Welch R, White S, Lindsay RM: An operating cost comparison between conventional and home quotidian hemodialysis. Am J Kidney Dis 42[Suppl]: 49–55, 2003
    1. Mohr PE, Neumann PJ, Franco SJ, Marainen J, Lockridge R, Ting G: The case for daily dialysis: Its impact on costs and quality of life. Am J Kidney Dis 37: 777–789, 2001
    1. Laupacis A: Economic evaluations in the canadian common drug review. Pharmacoeconomics 24: 1157–1162, 2006
    1. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ: Using effectiveness and cost-effectiveness to make drug coverage decisions: A comparison of Britain, Australia, and Canada. JAMA 302: 1437–1443, 2009
    1. Rocchi A, Menon D, Verma S, Miller E: The role of economic evidence in Canadian oncology reimbursement decision-making: To lambda and beyond. Value Health 11: 771–783, 2008
    1. Pauly RP, Maximova K, Coppens J, Asad RA, Pierratos A, Komenda P, Copland M, Nesrallah GE, Levin A, Chery A, Chan CT, CAN-SLEEP Collaborative Group : Patient and technique survival among a Canadian multicenter nocturnal home hemodialysis cohort. Clin J Am Soc Nephrol 5: 1815–1820, 2010
    1. Jaber BL, Schiller B, Burkart JM, Daoui R, Kraus MA, Lee Y, Miller BW, Teitelbaum I, Williams AW, Finkelstein FO, FREEDOM Study Group : Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances. Clin J Am Soc Nephrol 6: 1049–1056, 2011
    1. Lee CP, Zenios SA, Chertow GM: Cost-effectiveness of frequent in-center hemodialysis. J Am Soc Nephrol 19: 1792–1797, 2008
    1. Agar JW, Knight RJ, Simmonds RE, Boddington JM, Waldron CM, Somerville CA: Nocturnal haemodialysis: An Australian cost comparison with conventional satellite haemodialysis. Nephrology (Carlton) 10: 557–570, 2005
    1. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, Donaldson C: Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis 40: 611–622, 2002
    1. Pauly RP, Gill JS, Rose CL, Asad RA, Chery A, Pierratos A, Chan CT: Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant 24: 2915–2919, 2009
    1. Komenda P, Gavaghan MB, Garfield SS, Poret AW, Sood MM: An economic assessment model for in-center, conventional home, and more frequent home hemodialysis. Kidney Int 81: 307–313, 2012
    1. Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, Manns BJ: An economic evaluation of erythropoiesis-stimulating agents in CKD. Am J Kidney Dis 56: 1050–1061, 2010
    1. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M: Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 22: 2867–2878, 2007
    1. Manns B, Hemmelgarn B, Tonelli M, Au F, Chiasson TC, Dong J, Klarenbach S, Alberta Kidney Disease Network : Population based screening for chronic kidney disease: Cost effectiveness study. BMJ 341: c5869, 2010
    1. Canadian Agency for Drugs and Technologies in Health : Guidelines for the Economic Evaluation of Health Technologies, 3rd Ed., Ottawa, ON, Canada, Canadian Agency for Drugs and Technologies in Health, 2006
    1. Statistics Canada: Consumer Price Index for Canada [Health Care], 2010. Available at: Accessed February 1, 2013
    1. Manns B, Doig CJ, Lee H, Dean S, Tonelli M, Johnson D, Donaldson C: Cost of acute renal failure requiring dialysis in the intensive care unit: Clinical and resource implications of renal recovery. Crit Care Med 31: 449–455, 2003
    1. Barnieh L, Manns BJ, Klarenbach S, Mclaughlin K, Yilmaz S, Hemmelgarn BR: A description of the costs of living and standard criteria deceased donor kidney transplantation. Am J Transplant 11: 478–488, 2011
    1. Suri RS, Larive B, Sherer S, Eggers P, Gassman J, James SH, Lindsay RM, Lockridge RS, Ornt DB, Rocco MV, Ting GO, Kliger AS, Frequent Hemodialysis Network Trial Group : Risk of vascular access complications with frequent hemodialysis. J Am Soc Nephrol 24: 498–505, 2013
    1. Tonelli M, Klarenbach S, Jindal K, Manns B, Alberta Kidney Disease Network : Economic implications of screening strategies in arteriovenous fistulae. Kidney Int 69: 2219–2226, 2006
    1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725–1730, 1999
    1. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, Muirhead N: A study of the quality of life and cost-utility of renal transplantation. Kidney Int 50: 235–242, 1996
    1. Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, Pannu N, Ahmed SB, MacRae J, Scott-Douglas N, Jindal K, Quinn R, Culleton BF, Wiebe N, Krause R, Thorlacius L, Tonelli M: Overview of the Alberta Kidney Disease Network. BMC Nephrol 10: 30, 2009

Source: PubMed

3
Tilaa